default author photo

Nora Zeghib

Hôpital Franco-Britannique

France

  • Hôpital Franco-Britannique

SCHOLARLY PAPERS

1

DOWNLOADS

66

TOTAL CITATIONS

0

Scholarly Papers (1)

Actions:
Email selected abstracts
1.

Twice-Iri: A Randomized Phase Iii Study Comparing Modified Folfiri3-Aflibercept to Folfiri-Aflibercept as Second-Line Therapy in Patients with Metastatic Colorectal Cancer

Downloads 66

Twice-Iri: A Randomized Phase Iii Study Comparing Modified Folfiri3-Aflibercept to Folfiri-Aflibercept as Second-Line Therapy in Patients with Metastatic Colorectal Cancer

Number of pages: 24 Posted: 17 Dec 2024
Benoist Chibaudel, Olivier Dubreuil, Julien Taieb, Christophe Borg, Francois Ghiringhelli, Romain Cohen, Jean Baptiste Bachet, May Mabro, M Jary, Elisabeth Carola, Marie Dior, Candice Carola, Nathalie Perez-Staub, Hélène Marijon, Nora Zeghib, Hubert Richa, Stefano Kim, Morteza Raeisi, Thierry André and Aimery de Gramont
Hôpital Franco-Britannique, Groupe Hospitalier Diaconesses-Croix St-Simon, Université Paris Cité, University of Besançon - University Hospital Besançon, Centre Georges-François Leclerc - Department of Medical Oncology, affiliation not provided to SSRN, Sorbonne University - Hôpital Pitié-Salpêtrière, Department of Gastroenterology, Sainte Catherine Institute, Université Clermont Auvergne - CHU Clermont-Ferrand, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, Hôpital Franco-Britannique, Hôpital Franco-Britannique, Hôpital Franco-Britannique, Hôpital Franco-Britannique, affiliation not provided to SSRN, Fondation ARCAD, Sorbonne University and Hôpital Franco-Britannique
Downloads 39

Abstract:

Loading...

colorectal cancer, second-line, FOLFIRI, FOLFIRI3, aflibercept, antiangiogenic

TWICE-IRI: A Randomized Phase III Study Comparing Modified FOLFIRI3-Aflibercept to FOLFIRI-Aflibercept as Second-Line Therapy in Patients with Metastatic Colorectal Cancer

Number of pages: 24 Posted: 14 Mar 2025
Benoist Chibaudel, Olivier Dubreuil, Julien Taieb, Christophe Borg, Francois Ghiringhelli, Romain Cohen, Jean Baptiste Bachet, May Mabro, M Jary, Elisabeth Carola, Marie Dior, Candice Carola, Nathalie Perez-Staub, Hélène Marijon, Nora Zeghib, Hubert Richa, Stefano Kim, Morteza Raeisi, Thierry André and Aimery de Gramont
Hôpital Franco-Britannique, Groupe Hospitalier Diaconesses-Croix St-Simon, Université Paris Cité, University of Besançon - University Hospital Besançon, Centre Georges-François Leclerc - Department of Medical Oncology, affiliation not provided to SSRN, Sorbonne University - Hôpital Pitié-Salpêtrière, Department of Gastroenterology, Sainte Catherine Institute, Université Clermont Auvergne - CHU Clermont-Ferrand, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, Hôpital Franco-Britannique, Hôpital Franco-Britannique, Hôpital Franco-Britannique, Hôpital Franco-Britannique, affiliation not provided to SSRN, Fondation ARCAD, Sorbonne University and Hôpital Franco-Britannique
Downloads 27

Abstract:

Loading...

colorectal cancer, Second-line, FOLFIRI, FOLFIRI3, aflibercept, antiangiogenic, chemotherapy